News | News By Subject | News by Disease News By Date | Search News

Hepatitis (misc) News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
The $40 Billion NASH Market and the 3 Biotechs That Stand to Profit From it     11/2/2016
Bay Area's Tobira Strikes a $74.5 Million Evogliptin and Cenicriviroc Deal with Dong-A ST     4/11/2016
AbbVie (ABBV)’s Viekira Pak Clears Another Hurdle, 100% HCV-1b Clearance Rate in Phase III Trial     6/25/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Vertex Pharmaceuticals (MA) (VRTX) Tanks as FDA Puts Hold on Hep C Trial     7/30/2013
India Rejects Bayer AG (BAY.F) Plea Against Cheap Cancer Drug     3/5/2013
FDA Sees Safety Issue with Merck & Co., Inc. (MRK) Hepatitis Drug     4/25/2011
FDA Asks for More Data on Dynavax Technologies Corporation (DVAX)'s Hepatitis Vaccine     2/9/2009
Maxygen, Inc. (MAXY) and Roche (RHHBY) Terminate Development of Hepatitis Drug     11/26/2007
Enzon Pharmaceuticals, Inc. (ENZN) Sells 25 Percent Interest in Hepatitis C Drug     8/20/2007
Schering-Plough Corporation (SGP) Release: European Union's CHMP Adopts Positive Opinion For Shorter Course Of PEGINTRON(R) And REBETOL(R) Combination Therapy For Certain Hepatitis C Patients With Genotype 1 And Low Viral Load     7/29/2005
Valeant Pharmaceuticals International (VRX) Reports Positive Data From Pradefovir Mesylate Phase 2 Study; Results From 24-Week Interim Period Show Significant Decline In HBV Viral Load With No Evidence Of Nephrotoxicity     7/19/2005
Avexa Limited (AVX.AX) Back To The Drawing Board On Hepatitis B Program     6/30/2005

News from Around the Web
The Lab Breakthrough And The Two Men Behind Today’s Pricey Hepatitis C Cures     9/13/2016
Hospital Warns 213 Patients May Have Been Exposed To Hepatitis, HIV Due To Tampering of Drugs By Ex-Employee     2/26/2016
Diagnostics Hepatitis E Assay, Hannover Medical School Study     2/26/2016
Teen Girl Develops Hepatitis After Drinking Green Tea Bought Online     9/28/2015
Hepatitis Pills Spark Biggest Jump In Drug Costs In A Decade     3/11/2015
BioSpace’s Favorite FDA Tricks Or Treats     10/24/2014
US, EU Grant Accelerated Reviews Of Merck & Co., Inc. (MRK) Hepatitis Drug     1/7/2011
Roche Holding AG (RHHBF.PK), Johnson & Johnson (JNJ) and Biogen Idec, Inc. (Massachusetts) (BIIB) Prodded by FDA for More Neglected Disease Medicines     6/18/2010
University of Cincinnati Medical Center HEALTH LINE: New Drugs May Halt Rise In Hepatitis     5/22/2007
Liver Regeneration may be Simpler than Previously Thought     4/12/2007
Colitis Patients Need Better Immunization: Report     8/31/2006
Blood Test May Curb Liver Damage From TB Drug     7/26/2005
Potatoes Deliver Hepatitis Vaccine In Human Trials     2/15/2005
Tomato Vaccine     10/11/2004
FDA: Glaxo Vaccine Information Wrong     7/14/2004

Press Releases
Eiger Biopharma Completes Enrollment In Phase II LIMT HDV Study Of Pegylated Interferon Lambda In Hepatitis Delta Virus Infection     7/24/2017
Eiger Biopharma Announces Presentation Of Prevalence Data Of Hepatitis Delta Virus (HDV) Infection In The U.S. At Digestive Disease Week (DDW) In Chicago     5/8/2017
Eiger Biopharma Announces U.S. IND Filing Of Pegylated Interferon Lambda For Hepatitis Delta Virus Infection     5/3/2017
Merck & Co. (MRK) Announces New Phase II Data On Investigational Triple Combination Therapy MK-3682B For Chronic Hepatitis C     4/24/2017
Gilead (GILD) Announces Scientific Presentations Demonstrating Efficacy Of Harvoni (Ledipasvir/Sofosbuvir) In Special Patient Populations With HCV Infection     4/24/2017
Enanta Pharmaceuticals, Inc. Announces Eight Weeks Of Treatment With AbbVie (ABBV)’s Investigational, Pan-Genotypic, Ribavirin-Free HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates In Challenging-To-Treat Genotype 3 Chronic HCV Patients     4/21/2017
Gilead (GILD) Presents Data At The International Liver Congress 2017 Supporting The Efficacy And Safety Of Vemlidy In Patients With Chronic Hepatitis B After 96 Weeks, And Also After Switching From Viread     4/21/2017
Gilead (GILD) Announces Scientific Presentations Demonstrating Efficacy Of Harvoni (Ledipasvir/Sofosbuvir) In Special Patient Populations With HCV Infection     4/21/2017
Real-World Observational Study In The U.S. Veterans Affairs System Evaluating Use Of Merck & Co. (MRK)’s ZEPATIER (Elbasvir And Grazoprevir) Shows High Sustained Virologic Response Rates In Patients With Chronic Hepatitis C     4/21/2017
Enanta Pharmaceuticals, Inc. Announces 99 Percent SVR12 Rate In Chronic HCV Patients With Compensated Cirrhosis Treated With AbbVie (ABBV)'s Investigational, Pan-Genotypic, Ribavirin-Free Regimen Of Glecaprevir/Pibrentasvir (G/P)     4/20/2017
Gilead (GILD) Presents Data At The International Liver Congress 2017 Supporting The Efficacy And Safety Of Vemlidy In Patients With Chronic Hepatitis B After 96 Weeks, And Also After Switching From Viread     4/20/2017
Arrowhead Pharma (ARWR) Presents ARC-520 And ARC-521 Clinical Data At The International Liver Congress     4/20/2017
Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Completion Of Recruitment For Phase IIb Clinical Trials Of Myrcludex B In Chronic Hepatitis Delta     4/4/2017
Prime Therapeutics Study Finds 97 Percent Of Hepatitis C Patients Cured With Harvoni Treatment     3/21/2017
Cytuvax Starts Its Phase II BE RESPONDER! Study Effective Vaccination For Hepatitis B Non-Responders     3/14/2017

//-->